Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD) globally. Multiple risk factor management is essential in such patients to delay the disease progression \[[@CR1]\]; however, the management of blood glucose presents a particular challenge, with limited treatment options available beyond exogenous insulin therapy \[[@CR2]--[@CR5]\]. Patients with T2DM and CKD are at particular risk of hypoglycemia and its adverse consequences. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide a simple, oral, glucose-sensitive treatment option that does not increase the risk of hypoglycemia and does not confound the comorbidities that afflict many of the other drugs used to treat T2DM \[[@CR2]\]. In addition, DPP-4 inhibitors have been shown to be associated with no further decline in estimated glomerular filtration rate (eGFR) when treating patients with CKD \[[@CR2]\]. In recent years, several DPP-4 inhibitors have become available and have been extensively evaluated in patients with T2DM and varying degrees of renal impairment (RI). These studies have demonstrated good efficacy and tolerability of the DPP-4 inhibitor class in these patients, and have subsequently led to regulatory approval for the use in patients with T2DM and reduced eGFR due to CKD. Indeed, only exogenous insulin and DPP-4 inhibitors are indicated and now utilized widely across all thresholds of renal function, including end-stage renal disease (ESRD; Fig. [1](#Fig1){ref-type="fig"}) \[[@CR2], [@CR6]--[@CR11]\].Fig. 1Renal function threshold and recommended dose of DPP-4 inhibitors in renal impairment patients. *b.i.d.* twice daily, *DPP*-*4* dipeptidyl peptidase-4, *GFR* glomerular filtration rate, *o.d.* once daily, *Rl* renal impairment

Unlike linagliptin, with other DPP-4 inhibitors the drug exposure increases with decreasing renal function (Fig. [1](#Fig1){ref-type="fig"}). Thus, doses or dose frequencies are recommended to be reduced according to standard renal thresholds \[[@CR2], [@CR6]--[@CR12]\]. However, changes in renal function should be seen as a continuum; the thresholds from mild to moderate RI and from moderate to severe RI (see Fig. [1](#Fig1){ref-type="fig"} for definitions) are convenient delineations based on definitions of renal function that are in common usage \[[@CR13]\], rather than dictated by clear discontinuities in exposure. For instance, if a patient is seen at one visit with an eGFR of about 55 mL/min/1.73 m^2^ and a few months later at the next visit with an eGFR at approximately 45 mL/min/1.73 m^2^, the physician needs to be aware of this significant decline in renal function, but its impact on drug exposure will not be anywhere near the doubling of exposure implied by the following dosage strength or frequency recommendations. The labeling for sitagliptin, saxagliptin, and alogliptin recommends dosage strength adjustments depending on the level of renal function, with presumably no loss of efficacy \[[@CR2], [@CR6]--[@CR8]\]. Vildagliptin 50 mg efficacy is maintained when the frequency of dosing is reduced from twice daily in patients with normal renal function to once daily in patients with moderate or severe RI, in accordance with its label \[[@CR2], [@CR10]\]. The dose adjustments thus require regular monitoring of renal function, which is also good clinical practice because in these patients it is important to closely monitor renal disease progression. Other than the specifications for modifications in dose or dose frequency, there appears to be no difference between each DPP-4 inhibitor with respect to their safety and tolerability in patients with T2DM and CKD \[[@CR11]\].

In a recent review article on linagliptin \[[@CR14]\], the authors state that "other widely available DPP-4 inhibitors are excreted predominantly via the kidneys and require consideration/adjustment of dose or are not recommended in patients with moderate or severe RI or ESRD requiring dialysis". Such statements may cast doubt over the suitability of DPP-4 inhibitors other than linagliptin in treating patients with RI, implying that failure to adequately adjust the dose of these DPP-4 inhibitors may be associated with an increased risk of adverse effects and even nephrotoxicity. The safety and efficacy of the DPP-4 inhibitor calls as a whole has been well established in both patients with normal renal function as well as those with varying degrees of RI \[[@CR2], [@CR11]\]. These data are derived from patients with stable renal function at baseline, the question, however, is---what happens when a patient's CKD progresses resulting in an increase in exposure to unchanged drug or its metabolites consequent upon the declining GFR? In routine clinical practice, the failure to adjust the dose of DPP-4 inhibitor according to drug's summary of product characteristics and eGFR level is likely a fairly frequent occurrence \[[@CR15], [@CR16]\]. A key issue, therefore, is whether this failure in appropriate DPP-4 inhibitor dose adjustment in line with renal function translates into clinically meaningful consequences? Such concerns are further compounded by the fact that many other commonly prescribed drugs are associated with potential renal toxicity particularly when there is an increase in pharmacological exposure due to reduced clearance or catabolism \[[@CR17]\]. However, there is no evidence for such a link between higher exposure and renal toxicity with respect to any of the available DPP-4 inhibitors.

Finally, with regard to the risk of hypoglycemia with DPP-4 inhibitors, if the dose is not adjusted according to the label in patients with moderate/severe RI, it should be appreciated that DPP-4 inhibitors do not enhance hypoglycemia risk per se because elevations in glucagon-like peptide-1 and glucose insulinotropic polypeptide modulate insulin and glucagon secretion in a glucose-sensitive manner \[[@CR18]\].

Thus, recommendations to reduce the dose or dose frequency of DPP-4 inhibitors in patients with RI are not based on a risk of adverse effects or renal toxicity, but are aimed towards achieving drug exposure that yields the maximum efficacy. Of interest, in a study in which vildagliptin was dosed at either 50 mg once or twice daily in patients with ESRD, both dosing regimens were well tolerated \[[@CR19]\], with no clinically important differences noted between doses with respect to adverse events. Thus, any concern that accumulation of vildagliptin (or its renally excreted metabolites) results in an increase in renal or other toxicities is not supported by data. To our knowledge, this is also true for the entire DPP-4 inhibitor class.

In conclusion, DPP-4 inhibitors represent an appealing treatment option for the management of blood glucose control in people with T2DM and CKD. There is a wealth of literature, clinical experience, and regulatory review indicating that there is no evidence of any safety differences between the various individual agents within the class. It is important to remember that there is a continuum of renal function in patients with diabetes, with declining renal function associated with increasing age. As renal kidney dysfunction progresses, there is an increased risk of adverse clinical outcomes including acute kidney injury, falls, frailty, and mortality. Furthermore, in association with progressive RI, some coexisting conditions become more common and increase in severity, while the risk of adverse events associated with commonly used drugs such as metformin increases with declining renal function, in addition progression to ESRD can also occur in a small but significant group of people. The routine monitoring of renal function thus represents good clinical care of people with diabetes, beyond an appropriate dose adjustment of DPP-4 inhibitor. While there may be differences in the pharmacological profiles of the individual DPP-4 inhibitors in relation to renal function, there is no evidence that these translate into differences in terms of efficacy, safety, and nephrotoxic potential.

Current license recommendations for the marketed DPP-4 inhibitors with respect to renal function are based on extensive pharmacological and clinical trial data and represent the desire to ensure patient exposure to the minimal doses of drug required to ensure clinical efficacy. There is currently, however, no evidence to suggest that should an inadvertently inappropriate dosing of any DPP-4 inhibitor take place in the context of declining renal function translates into either nephrotoxicity or any increased risk of adverse events.
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